Drug Trial Radar · NCT00943826
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
Last checked: Nov 20, 2026Latest source record: Sep 25, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
921
Actual
Start
Jun 29, 2009
Primary completion
Feb 28, 2013
Study completion Sep 9, 2015
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jul 22, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This 2 arm study investigated the efficacy and safety of the addition of bevacizumab to the current standard of care (multimodality therapy of concurrent radiotherapy plus temozolomide followed by adjuvant temozolomide) as compared to the current standard of care alone. Participants were randomly assigned to either the bevacizumab (10 milligrams per kilogram (mg/kg) intravenously \[IV\] once every 2 week \[q2w\]) or the placebo arm, in combination with radiation therapy (total dose 60 Gray \[Gy\], administered as 2 Gy fractions, 5 days/week) plus temozolomide (75 milligrams per meter squared \[mg/m\^2\] oral administration \[po\] daily) for 6 weeks. After a 4 week treatment break, participants continued to receive bevacizumab (10 mg/kg IV q2w) or placebo, plus temozolomide (150-200 mg/m\^2 po daily on days 1-5 of each 4 week cycle) for 6 cycles of maintenance treatment or until disease progression or unacceptable toxicity, whichever occured first. Following the maintenance phase, bevacizumab (15 mg/kg iv every 3 weeks \[q3w\]) or placebo monotherapy continued. The time on study treatment was until disease progression.
Conditions
- Glioblastoma
Interventions
BevacizumabDrug
10 mg/kg intravenously q2w in the Concurrent and Maintenance Phases. 15 mg/kg intravenously q3w in the Monotherapy Phase.
TemozolomideDrug
75 mg/m\^2 once daily for 6 weeks, followed by 150-200 mg/m\^2 once daily on days 1-5 of six 4 week cycles.
Radiation therapyRadiation
30 fractions of 2 Gy delivered on days 1-5 per week for 6 weeks.
PlaceboDrug
Intravenously q2w in the Concurrent and Maintenance Phases and q3w in the Monotherapy Phase.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Co-Primary: Progression-free Survival (PFS) as Assessed by InvestigatorTime frame: Randomization until PFS Event [Until data cutoff= 31 March 2012 (up to 31.4 months)
- Co-Primary: Overall Survival (OS)Time frame: Randomization until OS Event (Until data cutoff= 28 February 2013 [up to 42.2 months])
Locations
133 sites in 24 countries. Site status is shown where the registry gives one.
University of Alabama At Birmingham; Neuro-Oncology
Birmingham, Alabama
UCLA
Los Angeles, California
University of Colorado
Aurora, Colorado
Moffitt Cancer Center
Tampa, Florida
Oncology-Evanston Nthwest Healthcare Kellogg Cancer Care Ctr
Evanston, Illinois
Henry Ford Health System
Detroit, Michigan
Hatton Research Institutes
Cincinnati, Ohio
Sarah Cannon Cancer Center and Research Institute
Nashville, Tennessee
University of Virgina
Charlottesville, Virginia
Prince of Wales Hospital; Department of Medical Oncology
Randwick, New South Wales, Australia
North Shore Private Hospital; Northern Specialist Centre
St Leonards, New South Wales, Australia
Royal North Shore Hospital; Department of Medical Oncology
St Leonards, New South Wales, Australia
Princess AleXandra Hospital; Department of Medical Oncology
Woolloongabba, Queensland, Australia
Calvary North Adelaide; North Adeliade Oncology Centre
North Adelaide, South Australia, Australia
Royal Melbourne Hospital; Hematology and Medical Oncology
Parkville, Victoria, Australia
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia
Clin Univ de Bxl Hôpital Erasme
Brussels, Belgium
Cliniques Universitaires St-Luc
Brussels, Belgium
UZ Antwerpen
Edegem, Belgium
AZ Sint Lucas (Sint Lucas)
Ghent, Belgium
CHU Sart-Tilman
Liège, Belgium
AZ Delta (Campus Wilgenstraat)
Roeselare, Belgium
Tom Baker Cancer Centre-Calgary
Calgary, Alberta, Canada
Cross Cancer Institute ; Dept of Medical Oncology
Edmonton, Alberta, Canada
BC Cancer Agency, Vancouver Clinic; Dept. of Medical Oncology
Vancouver, British Columbia, Canada
CancerCare Manitoba; Neuro-Oncology
Winnipeg, Manitoba, Canada
Hamilton Health Sciences - Juravinski Cancer Centre
Hamilton, Ontario, Canada
Cancer Centre of Southeastern Ontario; Kingston General Hospital
Kingston, Ontario, Canada
London Health Sciences Centre
London, Ontario, Canada
Ottawa Hospital Regional Cancer Centre; Neuro-Oncology
Ottawa, Ontario, Canada
Sunnybrook Odette Cancer Centre
Toronto, Ontario, Canada
Princess Margaret Hospital; Pencer Brain Tumour Centre, 18-727
Toronto, Ontario, Canada
Hopital Notre-Dame
Montreal, Quebec, Canada
McGill University; Montreal Neurological Institute; Oncology
Montreal, Quebec, Canada
Chuq - Hopital Hotel Dieu de Quebec
Québec, Quebec, Canada
Saskatoon Cancer Centre; Uni of Saskatoon Campus
Saskatoon, Saskatchewan, Canada
Aalborg Universitetshospital, Klinik Kirurgi-Kræft, Onkologisk afd.
Aalborg, Denmark
Righospitalet, Hæmatologisk Klinik
København Ø, Denmark
Odense Universitetshospital, Onkologisk Afdeling R
Odense, Denmark
Hopital Avicenne; Rhumatologie
Bobigny, France
Showing 40 of 133 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.